AREV Life Sciences Global Corp.

OTCPK:AREV.F Stock Report

Market Cap: US$2.1m

AREV Life Sciences Global Past Earnings Performance

Past criteria checks 0/6

AREV Life Sciences Global has been growing earnings at an average annual rate of 76.6%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been declining at an average rate of 96.1% per year.

Key information

76.6%

Earnings growth rate

82.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-96.1%
Return on equityn/a
Net Margin-3,322.8%
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How AREV Life Sciences Global makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AREV.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230000
30 Jun 230000
31 Mar 230-110
31 Dec 220-110
30 Sep 220-120
30 Jun 220-120
31 Mar 220-120
31 Dec 210-120
30 Sep 210-210
30 Jun 210-210
31 Mar 210-210
31 Dec 200-110
30 Sep 200-100
30 Jun 200-110
31 Mar 200-220
31 Dec 190-321
30 Sep 190-1021
30 Jun 190-1031
31 Mar 190-911
31 Dec 180-810
30 Sep 180-210
30 Jun 180-110
31 Mar 180-110
31 Dec 170-110
30 Sep 170-110
30 Jun 170000
31 Mar 170000
31 Dec 160000
30 Sep 160000
30 Jun 160000
31 Mar 160000
31 Dec 150000
30 Sep 150000
30 Jun 150000
31 Mar 150000
31 Dec 140000
30 Sep 140000
30 Jun 140000
31 Mar 140000

Quality Earnings: AREV.F is currently unprofitable.

Growing Profit Margin: AREV.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AREV.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AREV.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AREV.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).


Return on Equity

High ROE: AREV.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies